These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
Coronavirus-canSARVfinal_pdf_20200507.pdf (2.09 MB)

Coronavirus canSAR – a Data-Driven, AI-Enabled, Drug Discovery Resource for the Research Community

submitted on 12.05.2020, 09:30 and posted on 07.08.2020, 21:00 by Costas Mitsopoulos, Albert A. Antolin, Eloy Villasclaras Fernandez, Patrizio Di Micco, Ioan L. Micca, Joseph E Tym, Ka Hing Che, James Campbell, Domenico Sanfelice, Ian Collins, Paul Workman, Bissan Al-Lazikani

We describe an AI-enabled, integrated Coronavirus drug discovery knowledgebase, free for the research community. Its goal is to make accessible up to date information relevant to drug discovery for SARS-CoV-2 and other coronaviruses. It builds on great knowledge from across therapeutic areas and provides unbiased, systematic, objective information to empower the international effort.


Cancer Research UK (C35696/A23187)

Wellcome Trust (WT212969/Z/18/Z)

Wellcome Trust (WT204735/Z/16/Z)


Email Address of Submitting Author




United Kingdom

ORCID For Submitting Author


Declaration of Conflict of Interest

CM, AAA, EVF, PdM, ILM, JET, KHC, JC, DS, IC, PW and BAL are employees of the Institute of Cancer Research (ICR) which has a commercial interest in a range of drug targets. The ICR operates a Rewards to Inventors scheme through which employees of the ICR may receive financial benefit following commercial licensing. PW is a former employee of AstraZeneca and received research funding from Vernalis, Astex, AstraZeneca, BACIT and Sixth Element Capital/CRT Pioneer Fund. PW is a consultant/scientific advisory board member for NextechInvest, Storm Therapeutics, Astex Pharmaceuticals and CV6, and holds stock in Chroma Therapeutics, NextInvest and Storm Therapeutics. He is also a Non-Executive Director of Storm Therapeutics and the Royal Marsden NHS Trust and a Board Director of the nonprofit Chemical Probes Portal. BAL is currently or has been a consultant to Astex Pharmaceuticals, GSK, Astelas Pharma and Difiniens AG (member of Astra Zeneca group). BAL is a former employee of Inpharmatica Ltd. IC is currently or has been a consultant to Epidarex LLP, AdoRx Therapeutics and Enterprise Therapeutics, has received research funding from Astex, Merck KGaA, Janssen Biopharma, Monte Rosa Therapeutics and Sixth Element Capital/CRT Pioneer Fund, and holds stock in Monte Rosa Therapeutics AG. IC is a former employee of Merck Sharp & Dohme.